Carbidopa And Levodopa Capsule, Extended Release
NDC Package 70710-2139-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Carbidopa And Levodopa capsules is carbidopa and levodopa extended-release capsules are indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. This formulation utilizes a capsule, extended release delivery system. Marketed by Zydus Pharmaceuticals Usa Inc., this product is identified by NDC 70710-2139 and is authorized under FDA application NDA203312.

Identification & Billing

NDC Package Code
70710-2139-1
Package Description
100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE
Product Code
70710-2139
11-Digit Billing Format
70710213901
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 1600773 - carbidopa 23.75 MG / levodopa 95 MG 8HR Extended Release Oral Capsule
  • RxCUI: 1600773 - 8 HR carbidopa 23.75 MG / levodopa 95 MG Extended Release Oral Capsule
  • RxCUI: 1600773 - 8 HR Carbidopa 23.75 MG / L-DOPA 95 MG Extended Release Oral Capsule
  • RxCUI: 1600773 - carbidopa 23.75 MG / levodopa 95 MG 8 HR Extended Release Oral Capsule
  • RxCUI: 1600775 - carbidopa 36.25 MG / levodopa 145 MG 8HR Extended Release Oral Capsule

Clinical Specifications

Proprietary Name
Carbidopa And Levodopa
Non-Proprietary Name
Carbidopa And Levodopa
Substance Name
Carbidopa; Levodopa
Dosage Form
Capsule, Extended Release - A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Carbidopa and levodopa extended-release capsules are indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Regulatory & Marketing

Labeler Name
Zydus Pharmaceuticals Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA203312
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
10-20-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70710-2139-1 identifies a specific commercial package of 100 capsule, extended release in 1 bottle of Carbidopa And Levodopa, a human prescription drug labeled by Zydus Pharmaceuticals Usa Inc.. This capsule, extended release is formulated for oral use and contains carbidopa; levodopa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Pharmaceuticals Usa Inc. on October 20, 2025. The current certification is valid through December 31, 2026.

How is this Zydus Pharmaceuticals Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70710213901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70710-2139-1
11-Digit CMS (5-4-2)
70710-2139-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.